High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.94M
-81.58%
-0.570
+14%
1.81M
-6.22%
-0.580
+13.73%
1.81M
-51.06%
-0.578
+20.31%
Estimates Revision
The market is revising Downward the revenue expectations for MeiraGTx Holdings plc (MGTX) for FY2025, with the revenue forecasts being adjusted by -64.01% over the past three months. During the same period, the stock price has changed by 11.83%.
Revenue Estimates for FY2025
Revise Downward
-64.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+49.24%
In Past 3 Month
Stock Price
Go Up
+11.83%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast MGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGTX is 23.00 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.600
Low
15.00
Averages
23.00
High
30.00
Current: 8.600
Low
15.00
Averages
23.00
High
30.00
H.C. Wainwright
Mitchell Kapoor
Buy
initiated
$20
2025-11-24
Reason
H.C. Wainwright
Mitchell Kapoor
Price Target
$20
2025-11-24
initiated
Buy
Reason
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of MeiraGTx with a Buy rating and $20 price target. The firm has conviction that AAV-AQP1 for radiation-induced xerostomia is one of the most "risk-mitigated late-stage gene therapy programs in development." It recommends buying the shares ahead of the pivotal data in late 2026 or early 2027.
Piper Sandler
Allison M. Bratzel
Overweight
maintain
$28 -> $30
2025-11-11
Reason
Piper Sandler
Allison M. Bratzel
Price Target
$28 -> $30
2025-11-11
maintain
Overweight
Reason
Piper Sandler analyst Allison M. Bratzel raised the firm's price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the shares following the news that the company has entered a broad strategic collaboration with Eli Lilly (LLY) to develop and commercialize genetic medicines in ophthalmology. This deal grants the latter worldwide exclusive rights to MeiraGTx's AAVAIPL1 program in LCA4. In exchange, MeiraGTx receives an upfront payment of $75M and is eligible to receive over $400M in total milestone payments and tiered royalties on licensed products. Piper thinks this is a positive development for MeiraGTx, which not only helps validate the company's technology, but provides non-dilutive capital through both upfront and milestone payments. The firm remains a buyer.
Raymond James
Strong Buy
initiated
$29
2025-10-20
Reason
Raymond James
Price Target
$29
2025-10-20
initiated
Strong Buy
Reason
Raymond James initiated coverage of MeiraGTx with a Strong Buy rating and $29 price target, citing the company's fully integrated manufacturing platform, unique vector constructs, and full ownership and "a major commercial interest in two legitimately large commercial opportunities addressing significant unmet needs." The firm derives a fair value of $29 per share just by modeling MeiraGTx's two lead programs - AAV-AQP1 for xerostomia and AAV-GAD for Parkinson's disease - but adds that "pipeline optionality abounds."
Lucid Capital
NULL -> Buy
initiated
$50
2025-06-09
Reason
Lucid Capital
Price Target
$50
2025-06-09
initiated
NULL -> Buy
Reason
RBC Capital
Luca Issi
Buy
Maintains
$11 → $13
2025-03-17
Reason
RBC Capital
Luca Issi
Price Target
$11 → $13
2025-03-17
Maintains
Buy
Reason
RBC Capital raised the firm's price target on MeiraGTx to $13 from $11 and keeps an Outperform rating on the shares after its Q4 results. The company is very pleased with the terms of the deal announced with private AI company Hologen and notes that the process was competitive, the analyst tells investors in a research note. MeiraGTx is also planning to submit an MAA with UK regulators based on its LCA4 results with no need for additional studies, and is in discussions with FDA on a path forward, the firm adds.
Chardan Capital
Daniil Gataulin
Strong Buy
Maintains
$36
2025-02-24
Reason
Chardan Capital
Daniil Gataulin
Price Target
$36
2025-02-24
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for MeiraGTx Holdings PLC (MGTX.O) is -4.84, compared to its 5-year average forward P/E of -11.47. For a more detailed relative valuation and DCF analysis to assess MeiraGTx Holdings PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.47
Current PE
-4.84
Overvalued PE
21.18
Undervalued PE
-44.12
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
1.91
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
28.84
Undervalued EV/EBITDA
-25.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
27.27
Current PS
0.00
Overvalued PS
51.99
Undervalued PS
2.55
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 869.7% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
MGTX News & Events
Events Timeline
(ET)
2025-11-13
08:06:27
MeiraGTx anticipates sufficient funds to last through the second half of 2027.
2025-11-13
08:05:16
MeiraGTx announces Q3 earnings per share of 62 cents, compared to a loss of 55 cents in the previous year.
2025-11-11 (ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/5f5b8cf1c17f91120c44daf51c11e1e5a2e2de61587eae951984c113e8dd55ed.png)
Preview
7.5
11-10BenzingaEli Lilly Enhances Genetic Eye Disease Pipeline Through Collaboration with MeiraGTx on Gene Therapy
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/446a36a93150be7b8138e54ab77a4cfd38c63ab3f2d2ba8ca459ae84f80d90a3.png)
Preview
7.5
11-10SeekingAlphaEli Lilly Partners with MeiraGTx to Create Gene Therapies for Ocular Disorders
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
4.0
10-22BenzingaRaymond James Begins Coverage of MeiraGTx Holdings with Strong Buy Rating and Sets Price Target at $29
Sign Up For More News
People Also Watch
FAQ
What is MeiraGTx Holdings PLC (MGTX) stock price today?
What is MeiraGTx Holdings PLC (MGTX)'s business?
What is the price predicton of MGTX Stock?
What is MeiraGTx Holdings PLC (MGTX)'s revenue for the last quarter?
What is MeiraGTx Holdings PLC (MGTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MeiraGTx Holdings PLC (MGTX)'s fundamentals?
How many employees does MeiraGTx Holdings PLC (MGTX). have?